Retargeting T cells for HER2-positive tumor killing by a bispecific Fv-Fc antibody.
about
Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.Nanocell targeting using engineered bispecific antibodies.Fab-based bispecific antibody formats with robust biophysical properties and biological activityThe making of bispecific antibodiesT cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.
P2860
Retargeting T cells for HER2-positive tumor killing by a bispecific Fv-Fc antibody.
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Retargeting T cells for HER2-positive tumor killing by a bispecific Fv-Fc antibody.
@ast
Retargeting T cells for HER2-positive tumor killing by a bispecific Fv-Fc antibody.
@en
type
label
Retargeting T cells for HER2-positive tumor killing by a bispecific Fv-Fc antibody.
@ast
Retargeting T cells for HER2-positive tumor killing by a bispecific Fv-Fc antibody.
@en
prefLabel
Retargeting T cells for HER2-positive tumor killing by a bispecific Fv-Fc antibody.
@ast
Retargeting T cells for HER2-positive tumor killing by a bispecific Fv-Fc antibody.
@en
P2093
P2860
P1433
P1476
Retargeting T cells for HER2-positive tumor killing by a bispecific Fv-Fc antibody.
@en
P2093
Bhargavi M Boruah
Changzhen Liu
Huamin Han
P2860
P304
P356
10.1371/JOURNAL.PONE.0075589
P407
P577
2013-09-23T00:00:00Z